Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Position Decreased by JPMorgan Chase & Co.

JPMorgan Chase & Co. decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,126,092 shares of the biopharmaceutical company’s stock after selling 160,193 shares during the quarter. JPMorgan Chase & Co. owned about 4.82% of Intra-Cellular Therapies worth $428,131,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. True Wealth Design LLC bought a new stake in Intra-Cellular Therapies in the third quarter worth approximately $32,000. GAMMA Investing LLC boosted its holdings in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in Intra-Cellular Therapies during the fourth quarter worth $96,000. Wilmington Savings Fund Society FSB bought a new position in Intra-Cellular Therapies during the third quarter valued at about $97,000. Finally, Quarry LP lifted its position in shares of Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 1,300 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Trading Up 0.0 %

ITCI opened at $131.81 on Friday. The stock’s 50 day simple moving average is $129.12 and its 200-day simple moving average is $99.63. The stock has a market cap of $14.04 billion, a PE ratio of -151.50 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.87.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

ITCI has been the topic of a number of recent analyst reports. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Piper Sandler reiterated a “neutral” rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research report on Friday. They set a “hold” rating for the company. Finally, Canaccord Genuity Group downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Ten equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.